🟢 VERA is trading 4.8% up today ahead of FDA PDUFA date for atacicept

VERA is trading 4.8% up at $42.04 as traders position ahead of the FDA’s PDUFA action date for its IgA nephropathy drug, atacicept.

• The Biologics License Application for atacicept was accepted for Priority Review with an FDA target action date of July 7, 2026.
• This key regulatory catalyst is driving significant speculative interest in the stock during pre-market trading.